Anacetrapib
|
WikiDoc Resources for Anacetrapib |
|
Articles |
|---|
|
Most recent articles on Anacetrapib Most cited articles on Anacetrapib |
|
Media |
|
Powerpoint slides on Anacetrapib |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Anacetrapib at Clinical Trials.gov Clinical Trials on Anacetrapib at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Anacetrapib
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Anacetrapib Discussion groups on Anacetrapib Patient Handouts on Anacetrapib Directions to Hospitals Treating Anacetrapib Risk calculators and risk factors for Anacetrapib
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Anacetrapib |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Anacetrapib (MK-0859, Merck) is cholesteryl ester transfer protein inhibitor that raises high-density lipoprotein (HDL) cholesterol and reduces low-density lipoprotein (LDL) cholesterol. Cholesteryl ester transfer protein (CETP), also known as plasma lipid transfer protein, is a plasma protein that amasses triglycerides (TG) from VLDL cholesterol or LDL cholesterol and actively exchanges them for cholesteryl esters from HDL cholesterol. CETP inhibition leads to increase in size of HDL cholesterol particle and apolipoprotein A-I concentration, which is a major HDL protein. Development of Torcetrapib, the first CETP inhibitor, was halted during a phase III randomized clinical trial due to a 25% increase in cardiovascular adverse events within the cohort that received the active treatment. The increase in adverse events was thought to be secondary to "off target" toxicity including elevated aldosterone levels and consequent electrolyte abnormalities and elevated blood pressure.
Results of the Phase II DEFINE Study
Download the DEFINE slides here: media:DEFINE.ppt
DEFINEwas a Phase II randomized, double-blind, placebo-controlled trial designed to assess the safety and lipid-lowering efficacy of anacetrapib. Patients in the study had known coronary heart disease or were at an elevated risk for the devlopment of coronary heart disease. These patients had a LDL cholesterol level <100 and 99.3% were on statin therapy. Patients (1,623) were randomized to treatment with either 100 mg of anacetrapib or placebo daily for 18 months in a 1:1 fashion. The primary end point was percent change in LDL cholesterol from baseline at 24 weeks and safety and tolerability at 76 weeks. Percent change in HDL cholesterol from base line was a secondary end point.
The LDL cholesterol was reduced from 81 mg per deciliter (2.1 mmol per liter) to 45 mg per deciliter (1.2 mmol per liter) at 24 weeks in the anacetrapib group versus 82 mg per deciliter (2.1 mmol per liter) to 77 mg per deciliter (2.0 mmol per liter) among placebo treated patients (P<0.001). This represents a 39.8% reduction with anacetrapib realtive to placebo. Anacetrapib increased the HDL cholesterol level from 41 mg per deciliter (1.0 mmol per liter) to 101 mg per deciliter (2.6 mmol per liter) versus placebo which increased HDL from 40 mg per deciliter (1.0 mmol per liter) to 46 mg per deciliter (1.2 mmol per liter) (P<0.001). This represents a 138.1% increase in HDL associated with anacetrapib treatment versus placebo. Throughout the 76 weeks of therapy there were no changes in either systolic or diastolic blood pressure or electrolyte or aldosterone levels with anacetrapib as compared with placebo. In this modest sized study there were no liver function test abnormalities and no excess of myalgias. It should be noted that a study of this size may not exclude a risk of low frequency events such as Hy's law.
Normal 0 false false false EN-US X-NONE X-NONE It should be noted that the trial was underpowered to detect a meaningful difference in clinical events. The composite of death from cardiovascular causes, hospitalization from unstable angina, myocardial infarction or stroke occurred in 2% (16) of patients treated with Anacetrapib and 2.6% (21) in placebo group. The decrease in total cardiovascular events and total revascularizations was very impressive (8 vs. 28, P = 0.001).
Limitations of DEFINE
Normal 0 false false false EN-US X-NONE X-NONE Limitations of the study include the fact that this was a small population and the majority of patients were Caucasians. Further studies are also needed to further evaluate the effects of decreasing LDL cholesterol to extremely low levels. In the DEFINE study; Anacetrapib was discontinued in those patients with extremely low cholesterol levels. Larger studies are required to ensure the safety and tolerability of this drug. Given the promising results of this study, Merck has already launched the REVEAL HPS-3 TIMI-55 trial in collaboration with researchers at Harvard and Oxford. This study will include 30,000 patients with CHD who are already on statin therapy.